See more : Nippon Shinyaku Co., Ltd. (4516.T) Income Statement Analysis – Financial Results
Complete financial analysis of Jounce Therapeutics, Inc. (JNCE) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Jounce Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Yext, Inc. (YEXT) Income Statement Analysis – Financial Results
- Clancy Corp. (CCYC) Income Statement Analysis – Financial Results
- Audacy, Inc. (AUD) Income Statement Analysis – Financial Results
- Liuzhou Liangmianzhen Co., Ltd. (600249.SS) Income Statement Analysis – Financial Results
- Bondex Supply Chain Management Co., Ltd. (603836.SS) Income Statement Analysis – Financial Results
Jounce Therapeutics, Inc. (JNCE)
About Jounce Therapeutics, Inc.
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. It is also developing JTX-8064, an antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; JTX -1484 for myeloid; and JTX-1811, an anti-CCR8 monoclonal antibody designed to selectively deplete intra-tumoral T regulatory cells in the tumor microenvironment. Jounce Therapeutics, Inc. was incorporated in 2012 and is headquartered in Cambridge, Massachusetts.
| Metric | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 82.00M | 26.91M | 62.34M | 147.87M | 65.20M | 71.64M | 37.20M | 0.00 | 0.00 |
| Cost of Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | 82.00M | 26.91M | 62.34M | 147.87M | 65.20M | 71.64M | 37.20M | 0.00 | 0.00 |
| Gross Profit Ratio | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 103.27M | 88.98M | 78.69M | 67.14M | 70.05M | 67.80M | 34.90M | 22.13M | 11.24M |
| General & Administrative | 30.97M | 28.98M | 28.77M | 27.92M | 26.44M | 23.06M | 16.76M | 8.27M | 4.97M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.97M | 28.98M | 28.77M | 27.92M | 26.44M | 23.06M | 16.76M | 8.27M | 4.97M |
| Other Expenses | 1.46M | 199.00K | 1.29M | 4.05M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 134.24M | 117.96M | 107.46M | 95.06M | 96.50M | 90.86M | 51.66M | 30.40M | 16.21M |
| Cost & Expenses | 134.24M | 117.96M | 107.46M | 95.06M | 96.50M | 90.86M | 51.66M | 30.40M | 16.21M |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation & Amortization | 2.09M | 2.83M | 3.40M | 3.85M | 3.83M | 4.42M | 1.94M | 1.47M | 1.11M |
| EBITDA | -50.16M | -91.06M | -45.12M | 52.82M | -23.50M | -11.99M | -11.76M | -27.06M | -9.41M |
| EBITDA Ratio | -61.16% | -338.41% | -72.37% | 35.72% | -36.05% | -16.73% | -31.61% | 0.00% | 0.00% |
| Operating Income | -52.24M | -91.06M | -45.12M | 52.82M | -31.29M | -19.22M | -14.47M | -30.40M | -16.21M |
| Operating Income Ratio | -63.71% | -338.41% | -72.37% | 35.72% | -48.00% | -26.82% | -38.89% | 0.00% | 0.00% |
| Total Other Income/Expenses | 1.46M | 199.00K | 1.29M | 4.05M | 3.96M | 2.81M | 763.00K | 1.86M | 5.70M |
| Income Before Tax | -50.78M | -90.86M | -43.83M | 56.87M | -27.33M | -16.41M | -13.70M | -28.53M | -10.52M |
| Income Before Tax Ratio | -61.93% | -337.67% | -70.31% | 38.46% | -41.92% | -22.90% | -36.84% | 0.00% | 0.00% |
| Income Tax Expense | 135.00K | 15.00K | 14.00K | 46.00K | 46.00K | 36.00K | 763.00K | 1.86M | 5.70M |
| Net Income | -50.92M | -90.87M | -43.84M | 56.82M | -27.38M | -16.44M | -13.70M | -28.53M | -10.52M |
| Net Income Ratio | -62.10% | -337.73% | -70.33% | 38.43% | -41.99% | -22.95% | -36.84% | 0.00% | 0.00% |
| EPS | -0.99 | -1.82 | -1.24 | 1.72 | -0.84 | -0.55 | -0.45 | -1.54 | -0.48 |
| EPS Diluted | -0.99 | -1.82 | -1.24 | 1.66 | -0.84 | -0.55 | -0.45 | -1.54 | -0.48 |
| Weighted Avg Shares Out | 51.68M | 49.93M | 35.43M | 33.08M | 32.57M | 30.06M | 30.16M | 18.52M | 22.09M |
| Weighted Avg Shares Out (Dil) | 51.68M | 49.93M | 35.43M | 34.29M | 32.57M | 30.06M | 30.16M | 18.52M | 22.09M |
Bank of New York Mellon Corp Boosts Holdings in Jounce Therapeutics Inc (NASDAQ:JNCE)
Bank of New York Mellon Corp increased its stake in shares of Jounce Therapeutics Inc (NASDAQ:JNCE) by 158.5% in the fourth quarter, according to its most recent 13F filing with the SEC. The firm owned 220,131 shares of the company’s...
Agenus At The Time Of The Coronavirus
Agenus has a broad and deep pipeline into clinical development. The company is running two pivotal trials. AGEN1181 may have best in class properties that could
Reviewing Jounce Therapeutics (NASDAQ:JNCE) and Vical (NASDAQ:VICL)
Vical (NASDAQ:VICL) and Jounce Therapeutics (NASDAQ:JNCE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their profitability, valuation, institutional ownership, dividends, analyst recommendations, risk and earnings. Analyst...
Analysts Have Conflicting Sentiments on These Healthcare Companies: Jounce Therapeutics (JNCE), Intercept Pharma (ICPT) and Forty Seven (FTSV)
Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Jounce Therapeutics (JNCE), Intercept Pharma (ICPT) and
New Strong Buy Stocks for February 27th
Here are 5 stocks added to the Zacks Rank #1 (Strong Buy) List for today:
What's in Store for Jounce (JNCE) This Earnings Season?
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
What's in Store for Jounce (JNCE) This Earnings Season?
Investors will look forward to pipeline updates when clinical-stage immunotherapy company, Jounce (JNCE), reports Q4 results.
The Daily Biotech Pulse: Tonix Slumps On Failed Study, Applied Genetic Announces Offering, Beam Therapeutics, PPD Price IPOs
The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks that hit 52-week highs Feb. 5.) Alector Inc (NASDAQ: ALEC ) (announced granting ...
Stock Analysts' Updated EPS Estimates for February, 5th (ABC, ACSO, ANTO, BBOX, BME, BNP, BOO, BREE, BT.A, BYG)
Stock Analysts’ updated eps estimates for Wednesday, February 5th: Abcam (LON:ABC) had its add rating reaffirmed by analysts at Peel Hunt. Accesso Technology Group (LON:ACSO) had its under review rating reaffirmed by analysts at Peel Hunt. Antofagasta (LON:ANTO) was upgraded...
The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus
Biotech stocks see-sawed through the week ended Jan. 31 and ended the month lower overall. Big pharma earnings of the week were mostly disappointing. Pfizer Inc. (NYSE: PFE ) reported disappointing fourth-quarter ...
Source: https://incomestatements.info
Category: Stock Reports